Xu, M., Thakkar, D., Panse, G., Yan, J., Minden, M., Zandi, S., … Dave, S. (2023). Mutations in ASXL1 and/or TET2 Identify a Subset with Worse Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasms. In LABORATORY INVESTIGATION (Vol. 103, pp. S1258–S1259).

Xu, Mina, Devang Thakkar, Gauri Panse, Jiong Yan, Mark Minden, Sasan Zandi, Kikkeri Naresh, et al. “Mutations in ASXL1 and/or TET2 Identify a Subset with Worse Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasms.” In LABORATORY INVESTIGATION, 103:S1258–59, 2023.

Xu M, Thakkar D, Panse G, Yan J, Minden M, Zandi S, et al. Mutations in ASXL1 and/or TET2 Identify a Subset with Worse Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasms. In: LABORATORY INVESTIGATION. 2023. p. S1258–9.

Xu, Mina, et al. “Mutations in ASXL1 and/or TET2 Identify a Subset with Worse Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasms.” LABORATORY INVESTIGATION, vol. 103, no. 3, 2023, pp. S1258–59.

Xu M, Thakkar D, Panse G, Yan J, Minden M, Zandi S, Naresh K, Czader M, Love C, Happ L, Koff J, Jaye D, Michael C, Arildsen MA, Juskevicius R, Soliman D, Louissaint A, Mckinney M, Sojitra P, Yin CC, Ondrejka S, Tse E, Dave S. Mutations in ASXL1 and/or TET2 Identify a Subset with Worse Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasms. LABORATORY INVESTIGATION. 2023. p. S1258–S1259.